close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Selected Research Bibliography

In the rapidly growing field of viscosupplementation, keeping up with the latest clinical research can be difficult. To help you find the information you need, we’ve assembled a comprehensive list of recent articles and scientific studies on the efficacy and safety of SYNVISC®.

SYNVISC Efficacy

1. Raman R, Dutta A, Day N, Shaw CJ, Johnson GV. The efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee—a prospective randomized clinical trial. Poster presented at: American College of Rheumatology Annual Scientific. Meeting; November 10-15, 2006; Washington, DC.
View Abstract

2. Wang C-T, Lin J, Chang C-J, Lin Y-T, Hou S-M. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg.2004; 86-A: 538-545.
View Abstract

3. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: A 26 week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998; 20:410-423.
View Abstract

4. Caborn D, Rush J, Lanzer W, Parenti D, Murray C, on behalf of the Synvisc 901 Study Group. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol.2004; 31:333-343.
View Abstract

5. Bagga H, Burkhardt D, Sambrook P, March L. Long-term effects of intra-articular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006; 33:946-950.
View Abstract

Return to top

SYNVISC Safety

6. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin.2005; 21:1261-1269.
View Abstract

7. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin.2003; 19:575-580.
View Abstract

8. Raynauld J, Goldsmith C, Bellamy N, Torrance G, Polisson R, Belovich D, Pericak D, Tugwell P. Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis & Cartilage. 2005; 13:111-119.
View Abstract

9. Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: A retrospective review. J Surg & Orthopaedic Advances. 2006; 15(1):53-59.
View Abstract

10. Waddell DD, Cefalu C, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg. 2005; 18:7-15.
View Abstract

Return to top




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)